Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psor...
Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-gene...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...
Antengene Corporation Limited, a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing fir...
300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicab...
Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announc...
Vanda Pharmaceuticals Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ims...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced th...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced that its next-generation TRK inhibitor, zurletrectinib (ICP-72...
Eurofins Consumer Product Testing Vietnam has completed a major expansion, seeing the laboratory move to a purpose-built 7,000 sq. m laboratory in Ho Chi...
Resmed , the leading health technology company focused on sleep, breathing and care delivered in the home, announced it has received U.S. Food and Drug A...
Collaboration with Science Tokyo spinout underscores GlycoNex's integrated antibody development and manufacturing capabilities in support of first-in-cla...
Pillar Biosciences and AstraZeneca announced an expansion of their existing laboratory access program for NGS-based kitted liquid biopsy tumor profi...
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Co...
© 2025 Biopharma Boardroom. All Rights Reserved.
